Why did a patient who was taking carvedilol, isosorbide (a nitrate), and Entresto (sacubitril/valsartan) and who refused torsemide develop hypotension after an initial blood pressure of 143/83 mmHg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Why Did This Patient Develop Hypotension?

This patient experienced a delayed, profound hypotensive episode most likely due to the additive vasodilatory and blood pressure-lowering effects of Entresto (sacubitril/valsartan), carvedilol, and isosorbide acting synergistically, with the hypotension manifesting 7 hours after refusing the diuretic torsemide—a timeline consistent with documented delayed-onset hypotension from Entresto. 1, 2

Mechanism of the Hypotensive Episode

The combination of three potent blood pressure-lowering agents created a "perfect storm":

  • Entresto (sacubitril/valsartan): Causes vasodilation through dual neprilysin inhibition and angiotensin II receptor blockade. Hypotension is the most likely result of overdosage or excessive effect 1. Importantly, first-dose hypotension from Entresto can have delayed onset occurring 8-18 hours after administration and can be prolonged for 3-6 days 2.

  • Carvedilol: Produces both β-adrenergic blockade (reducing cardiac output) and α1-receptor blockade (causing vasodilation and reducing peripheral vascular resistance). Blood pressure is lowered more in the standing than supine position, and postural hypotension can occur 3. The drug causes significant reductions in mean arterial pressure, particularly affecting diastolic blood pressure 4.

  • Isosorbide (nitrate): Induces vasodilatation, venous pooling, reduced cardiac output, and hypotension 5. The vasodilatory effects contribute directly to blood pressure reduction.

Why the 7-Hour Delay?

The timing is critical here. Entresto-related hypotension has been documented to have delayed onset of 8-18 hours after the first dose 2, which aligns with this patient's 7-hour timeline. The initial blood pressure of 143/83 mmHg likely represented a period before peak drug effects accumulated. The subsequent drop to 85/55 mmHg occurred as:

  1. Drug absorption and metabolism reached peak levels
  2. Synergistic vasodilatory effects compounded
  3. The absence of torsemide (a diuretic) meant no additional volume depletion, but also no counterbalancing effect on the vasodilatory cascade

Clinical Context from Guidelines

The 2025 ESC Heart Failure Association consensus specifically warns that sacubitril/valsartan is more likely to lead to symptomatic hypotension compared to other heart failure medications 6. In the PARADIGM-HF trial, 11.1% of patients experienced symptomatic hypotension, and hypotension was a key predictor of non-completion during the run-in phase 6.

The guidelines emphasize that patients with baseline systolic blood pressure 100-110 mmHg are at particular risk, though this patient started higher 6, 7. However, the combination therapy dramatically increased risk beyond what would be expected from baseline blood pressure alone.

Key Risk Factors in This Case

The combination of Entresto + beta-blocker + nitrate creates multiplicative hypotensive risk because:

  • Entresto blocks both neprilysin and angiotensin II (dual vasodilation)
  • Carvedilol reduces cardiac output (β-blockade) AND causes vasodilation (α1-blockade)
  • Isosorbide adds direct venous and arterial vasodilation
  • All three mechanisms converge on reducing blood pressure through different pathways simultaneously

The 2022 AHA/ACC/HFSA guidelines note that in PARAGON-HF, the occurrence of hypotension favored the control group, and sacubitril/valsartan was associated with higher incidence of hypotension 8.

What Should Have Been Done Differently

Patients initiating or up-titrating Entresto should have gradual dose escalation, particularly when combined with other vasodilators 7. The TITRATION study showed that patients with lower systolic blood pressure (100-110 mmHg) achieved better treatment success with gradual 6-week up-titration (80%) compared to rapid 3-week up-titration (69%) 7.

Critical monitoring points:

  • Blood pressure should be checked at 1-2 hours (for carvedilol peak effect) 3
  • Again at 6-8 hours (for potential delayed Entresto effect) 2
  • Patient should be counseled about orthostatic symptoms
  • Consider holding or reducing nitrate dose when initiating Entresto

Common Pitfalls to Avoid

  1. Assuming initial normal blood pressure means safety: The delayed hypotensive effect of Entresto means early blood pressure readings don't predict later drops 2

  2. Underestimating drug-drug interactions: The combination of three vasodilatory mechanisms (Entresto, carvedilol's α1-blockade, and nitrates) creates exponential rather than additive risk

  3. Not adjusting for medication timing: When postural hypotension occurs with carvedilol, it is transient and uncommon when administered with food at recommended starting doses with close titration 3

  4. Ignoring the "wet and warm" vs "dry" status: In euvolemic or "dry" patients, aggressive vasodilation without volume loading can precipitate severe hypotension 6

References

Related Questions

Can sacubitril-valsartan be used in a patient with hypotension?
In an elderly male taking sacubitril‑valsartan (Entresto) and chlorthalidone 25 mg, what is the next antihypertensive agent to add?
Can a patient be switched from losartan 100 mg once daily to valsartan 160 mg once daily for hypertension with heart failure?
In a heart failure patient who develops cholestasis while on sacubitril‑valsartan (Entresto), what steps should be taken regarding the drug and what alternative heart‑failure regimen is recommended?
Is Entresto (sacubitril/valsartan) safe in patients with systolic blood pressure below 100 mmHg?
Should dicyclomine 20 mg be taken on a scheduled basis (daily) or only as needed (pro re nata)?
Is the use of tesamorelin (a growth hormone‑releasing factor analog) indicated for longevity or anti‑aging purposes in a healthy adult without HIV‑associated visceral adiposity?
In an 80‑plus‑year‑old patient with chronic dysuria and cystitis, chronic kidney disease (glomerular filtration rate 25‑29 mL/min), contraindications to trimethoprim‑sulfamethoxazole (due to methenamine and losartan), levofloxacin (due to amiodarone), and an allergy to cephalexin, whose urine culture grew Pseudomonas aeruginosa 10‑15 × 10³ CFU/mL with mixed flora, does she have a urinary tract infection?
How should I triage a patient over the phone who has thrombocytopenia with a platelet count of 88 × 10⁹/L?
In a patient with stage 3 chronic kidney disease (eGFR ≈ 41 mL/min/1.73 m², creatinine ≈ 1.5 mg/dL, BUN ≈ 32 mg/dL), mild anemia (RBC ≈ 4.21 ×10⁶/µL, RDW ≈ 15.2 %), thrombocytopenia (platelets ≈ 103 ×10³/µL), macrocytosis, elevated vitamin B12, and low serum iron, what is the most likely diagnosis and how should it be treated?
What quantity (total volume) should be written on the prescription for lorazepam oral concentrate 2 mg/mL based on the prescribed dose and dosing schedule?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.